Heron Therapeutics, Inc. announced on November 4, 2024, the appointment of Michael Kaseta to its Board of Directors. Mr. Kaseta brings extensive experience in corporate finance, business strategy, and the commercialization of biopharma products from both large pharmaceutical and small biotech companies.
Mr. Kaseta currently serves as the Chief Financial Officer and Chief Operating Officer of Liquidia Corporation, a biopharmaceutical company. His prior roles include Chief Financial Officer at Aerami Therapeutics, Inc. and Aralez Pharmaceuticals, Inc., as well as eleven years in various financial leadership positions at Sanofi S.A., culminating in the CFO role at Sanofi North America, Global Services.
Heron's CEO, Craig Collard, expressed confidence that Mr. Kaseta's deep experience in commercial biotechnology leadership will be a valuable asset to the Board. This appointment is expected to support the company's efforts to drive continued growth of its proprietary product portfolio focused on acute and oncology care.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.